About
Thomas A. Smeenk is the co-founder, President, CEO, and director of Hemostemix Inc., a Canadian clinical-stage regenerative-medicine company developing ACP-01. His prior work includes executive roles in mining and business development; he founded and financed TheraVitae, the predecessor company to Hemostemix.
Areas of interest
regenerative medicinecell therapybiotechclinical researchvascular diseasemineral explorationproject financebusiness development